Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Accumulated Depreciation: 2019-2025

Historic Accumulated Depreciation for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Sep 2025 value amounting to $20.1 million.

  • 4D Molecular Therapeutics' Accumulated Depreciation rose 29.52% to $20.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year increase of 29.52%. This contributed to the annual value of $16.6 million for FY2024, which is 39.00% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Accumulated Depreciation stood at $20.1 million for Q3 2025, which was up 6.71% from $18.8 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' Accumulated Depreciation's 5-year high stood at $20.1 million during Q3 2025, with a 5-year trough of $4.2 million in Q1 2021.
  • For the 3-year period, 4D Molecular Therapeutics' Accumulated Depreciation averaged around $14.3 million, with its median value being $14.3 million (2024).
  • Data for 4D Molecular Therapeutics' Accumulated Depreciation shows a peak YoY surged of 61.32% (in 2023) over the last 5 years.
  • 4D Molecular Therapeutics' Accumulated Depreciation (Quarterly) stood at $5.3 million in 2021, then surged by 45.13% to $7.7 million in 2022, then spiked by 54.40% to $11.9 million in 2023, then skyrocketed by 39.00% to $16.6 million in 2024, then climbed by 29.52% to $20.1 million in 2025.
  • Its Accumulated Depreciation stands at $20.1 million for Q3 2025, versus $18.8 million for Q2 2025 and $17.6 million for Q1 2025.